Head-to-head evidence
ASC30 vs CX11
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
CX11
Developed by Corxel Pharmaceuticals
NCT07011797 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled Phase 2 trial, 250 adults with obesity were assigned to CX11 at several doses or placebo for 26 weeks, with follow-up to 36 weeks. The company reported that the trial's weight-loss primary endpoints were met, with weight loss reaching up to 11.5% by week 36 and continuing without a plateau; gastrointestinal side effects were the most common safety finding.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT07652047 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · CX11's landscape